Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: An analysis from HELLAS-FH registry.
Barkas F, Rizos CV, Liamis G, Skoumas I, Garoufi A, Rallidis L, Kolovou G, Tziomalos K, Skalidis E, Sfikas G, Kotsis V, Doumas M, Anagnostis P, Lambadiari V, Anastasiou G, Koutagiar I, Attilakos A, Kiouri E, Kolovou V, Polychronopoulos G, Koutsogianni AD, Zacharis E, Koumaras C, Antza C, Boutari C, Liberopoulos E. Barkas F, et al. Among authors: skoumas i. J Clin Lipidol. 2024 Jan 24:S1933-2874(24)00005-9. doi: 10.1016/j.jacl.2024.01.005. Online ahead of print. J Clin Lipidol. 2024. PMID: 38331687
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.
Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Paletas K, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS, Mikhailidis DP; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Athyros VG, et al. Curr Vasc Pharmacol. 2011 Nov;9(6):647-57. doi: 10.2174/157016111797484080. Curr Vasc Pharmacol. 2011. PMID: 21476961 Clinical Trial.
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Achimastos A, Alexandrides T, Alexopoulos D, Athyros V, Bargiota A, Bilianou E, Chrysochoou C, Drogari E, Elisaf M, Ganotakis E, Goudevenos I, Ioannidis I, Kolovou G, Kotsis V, Lekakis I, Liberopoulos E, Melidonis A, Nikolaou V, Ntaios G, Papanas N, Pappas S, Pitsavos C, Rallidis L, Richter D, Skoumas I, Tentolouris N, Tousoulis D, Tselepis A, Tsioufis K, Tziakas D, Tziomalos K, Vardas P, Vlachopoulos C, Vlahakos D. Achimastos A, et al. Among authors: skoumas i. Hormones (Athens). 2016 Jan-Mar;15(1):8-14. doi: 10.14310/horm.2002.1659. Hormones (Athens). 2016. PMID: 27086681 Free article.
An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN. Rizos CV, et al. Among authors: skoumas i. Hormones (Athens). 2017 Jul;16(3):200-204. doi: 10.14310/horm.2002.1749. Hormones (Athens). 2017. PMID: 29278517 Free article.
Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias.
Vlachopoulos C, Koutagiar I, Terentes-Printzios D, Skoumas I, Rigatou A, Miliou A, Skliros AN, Pantou S, Filis K, Tousoulis D. Vlachopoulos C, et al. Among authors: skoumas i. Hellenic J Cardiol. 2019 Mar-Apr;60(2):124-128. doi: 10.1016/j.hjc.2018.05.003. Epub 2018 May 25. Hellenic J Cardiol. 2019. PMID: 29807195 Free article.
Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
Rizos CV, Elisaf MS, Skoumas I, Tziomalos K, Kotsis V, Rallidis L, Garoufi A, Athyros VG, Skalidis E, Kolovou G, Koutagiar I, Papagianni M, Antza C, Katsiki N, Ganotakis E, Liberopoulos EN. Rizos CV, et al. Among authors: skoumas i. Atherosclerosis. 2018 Oct;277:308-313. doi: 10.1016/j.atherosclerosis.2018.08.017. Atherosclerosis. 2018. PMID: 30270064
PCSK9 inhibitors in clinical practice: Novel directions and new experiences.
Rallidis LS, Skoumas I, Liberopoulos EN, Vlachopoulos C, Kiouri E, Koutagiar I, Anastasiou G, Kosmas N, Elisaf MS, Tousoulis D, Iliodromitis E. Rallidis LS, et al. Among authors: skoumas i. Hellenic J Cardiol. 2020 Jul-Aug;61(4):241-245. doi: 10.1016/j.hjc.2019.10.003. Epub 2019 Nov 26. Hellenic J Cardiol. 2020. PMID: 31783124 Free article.
Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake.
Vlachopoulos C, Koutagiar I, Skoumas I, Terentes-Printzios D, Zacharis E, Kolovou G, Stamatelopoulos K, Rallidis L, Katsiki N, Bilianou H, Liberopoulos E, Miliou A, Kafouris P, Georgakopoulos A, Gardikioti V, Tousoulis D, Anagnostopoulos CD. Vlachopoulos C, et al. Among authors: skoumas i. JACC Cardiovasc Imaging. 2019 Dec;12(12):2573-2574. doi: 10.1016/j.jcmg.2019.09.024. JACC Cardiovasc Imaging. 2019. PMID: 31806185 Free article. No abstract available.
61 results